Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Precision Medicine for Cancer Care
share announcement

Precision Medicine for Cancer Care

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 3552

Special Issue Editor

Dr. Quincy S.C. Chu

E-Mail Website
Guest Editor
Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada.
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In this Issue, our goal is to solicit primary research and review articles on the role, adaptation impact, and future of precision medicine in the management of cancer patients. 

Precision medicine is originally defined as the use of genetic information to help guide the choice of the most effective therapy for patients. Precision medicine for cancer therapeutics began with the use of hormone therapy in the management of hormone receptors in breast cancer patients. In recent years, there has been an exponential increase in the number of protein and genetic markers being used in selecting the right cancer patients for the right cancer therapy. In this Issue, we would like to solicit manuscripts related to the current status of precision medicine markers in the diagnosis, prognosis, and therapy of various malignancies, the barriers to the adaptation of precision medicine in cancer therapy, and the future of precision medicine in oncology. 

Dr. Quincy S.C. Chu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • next-generation sequencing
  • oncogenic drivers
  • cancer therapeutics
  • prognosis
  • outcome

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 755 KiB  
Article
The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study
by Covadonga Martí, Laura Yébenes, José María Oliver, Elisa Moreno, Laura Frías, Alberto Berjón, Adolfo Loayza, Marcos Meléndez, María José Roca, Vicenta Córdoba, David Hardisson, María Ángeles Rodríguez and José Ignacio Sánchez-Méndez
Curr. Oncol. 2022, 29(4), 2199-2210; https://doi.org/10.3390/curroncol29040179 - 23 Mar 2022
Cited by 6 | Viewed by 3073
Abstract
Purpose: Neoadjuvant endocrine treatment (NET) has become a useful tool for the downstaging of luminal-like breast cancers in postmenopausal patients. It enables us to increase breast- conserving surgery (BCS) rates, provides an opportunity for us to assess in vivo NET effectiveness, and allows [...] Read more.
Purpose: Neoadjuvant endocrine treatment (NET) has become a useful tool for the downstaging of luminal-like breast cancers in postmenopausal patients. It enables us to increase breast- conserving surgery (BCS) rates, provides an opportunity for us to assess in vivo NET effectiveness, and allows us to study any biological changes that may act as valid biomarkers. The purpose of this study was to evaluate the safety and effectiveness of NET, and to assess the role of Ki67 proliferation rate changes as an indicator of endocrine responsiveness. Methods: From 2016 to 2020, a single-institution cohort of patients, treated with NET and further surgery, was evaluated. In patients with Ki67 ≥ 10%, a second core biopsy was performed after four weeks. Information regarding histopathological and clinical changes was gathered. Results: A total of 115 estrogen receptor-positive (ER+)/HER2-negative patients were included. The median treatment duration was 5.0 months (IQR: 2.0–6.0). The median maximum size in the surgical sample was 40% smaller than the pretreatment size measured by ultrasound (p < 0.0001). The median pretreatment Ki67 expression was 20.0% (IQR: 12.0–30.0), and was reduced to 5.0% (IQR: 1.8–10.0) after four weeks, and to 2.0% (IQR: 1.0–8.0) in the surgical sample (p < 0.0001). BCS was performed on 98 patients (85.2%). No pathological complete responses were recorded. A larger Ki67 fold change after four weeks was significantly related to a PEPI score of zero (p < 0.002). No differences were observed between luminal A- and B-like tumors, with regard to fold change and PEPI score. Conclusions: In our cohort, NET was proven to be effective for tumor size and Ki67 downstaging. This resulted in a higher rate of conservative surgery, aided in therapeutic decision making, provided prognostic information, and constituted a safe and well-tolerated approach. Full article
(This article belongs to the Special Issue Precision Medicine for Cancer Care)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop